AACP
FENC icon

Advantage Alpha Capital Partners’s Fennec Pharmaceuticals FENC Stock Holding History

Advantage Alpha Capital Partners’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-52,876
Closed -$264K – 164
2024
Q3 		$264K Buy
+52,876
New +$306K 0.06% 162

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advantage Alpha Capital Partners's FENC Position: Q4 2024 in Review

Advantage Alpha Capital Partners sold out of Fennec Pharmaceuticals (FENC) in Q4 2024, closing a stake of 52,876 shares — an estimated $264K sold.

Advantage Alpha Capital Partners first reported a position in FENC in Q3 2024 and held it in 1 quarter. The position peaked at $264K in Q3 2024. 64 funds tracked by Wall St. Rank hold FENC as of Q4 2024.

  • Advantage Alpha Capital Partners reported no remaining Fennec Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 52,876 Fennec Pharmaceuticals shares in Q4 2024, an estimated $264K.
  • Advantage Alpha Capital Partners first reported a position in Fennec Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's Fennec Pharmaceuticals position peaked at $264K in Q3 2024.
  • 64 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2024, filed 11 Feb 2025.